New York, June 26, 2023 (GLOBE NEWSWIRE) — CertiK, the global leader in blockchain security, is excited to announce the successful completion of a security audit for OKX’s BRC-20 token contracts. This is a significant step in bringing Ordinals to the Bitcoin blockchain, a milestone in the crypto and blockchain
Danilo Iervolino and Chiara Giugliano MILAN, Italy, June 26, 2023 (GLOBE NEWSWIRE) — Ferretti’s luxury yachts are just one step away from Piazza Affari. The Group, currently listed on the Hong Kong Stock Exchange, announced the successful completion of its IPO for listing on the Milan Stock Exchange. The offer
KUALA LUMPUR, Malaysia, June 26, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) announced that it has proposed to acquire a 51% stake in Cogia GmbH from Cogia AG for a purchase consideration of USD5 million. The purchase consideration will be settled by way
WillScot Mobile Mini’s PRORACK™ PHOENIX, June 26, 2023 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible space and storage solutions, including mobile office and portable storage containers, today announced PRORACK, a proprietary space management solution
The Yacht Club de Monaco celebrates the 70th Anniversary MONACO, June 26, 2023 (GLOBE NEWSWIRE) — The Yacht Club de Monaco celebrates 70 years since its foundation. The ceremony was attended by 1,500 people who gathered on the YCM’s quay to celebrate the anniversary. The Yacht Club de Monaco “has
Fund will invest in key technologies for carbon reduction, removal and compensation of emissions as well as carbon economy opportunities Delft, Netherlands and Vancouver, Canada, June 25, 2023 (GLOBE NEWSWIRE) — Chrysalix Venture Capital, an experienced and early stage industrial sustainability investor, announces the first close of its fifth fund,
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting
